Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS2009 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- CStone Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CS2009 + paclitaxel is a combination therapy comprising CS2009, a tri-specific antibody, and the taxane chemotherapy paclitaxel. CS2009 is engineered to target programmed death-ligand 1 (PD-L1), the costimulatory receptor 4-1BB (CD137), and human serum albumin (HSA). Its mechanism involves conditional 4-1BB activation that is strictly dependent on PD-L1 binding, aiming to localize immune stimulation to the tumor microenvironment and minimize systemic inflammatory toxicities, while the HSA component extends its pharmacokinetic profile. Paclitaxel complements this by binding to tubulin and stabilizing microtubules, which inhibits mitosis and leads to cancer cell death. Developed by CStone Pharmaceuticals, this combination is being evaluated in Phase I/II trials for advanced solid tumors, including lung, gastric, and ovarian cancers.
- Other names
- CS2009 + paclitaxelCS2009 plus paclitaxelCS-2009 plus paclitaxelCS 2009 plus paclitaxel
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on CS2009 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS2009 + paclitaxel.